Foretinib (GSK1363089): ATP-Competitive Multikinase Inhibitor for Cancer Research

Executive Summary: Foretinib (GSK1363089) is a small-molecule, ATP-competitive inhibitor that targets multiple receptor tyrosine kinases implicated in cancer biology, including VEGFR, HGFR/Met, and others (APExBIO). It demonstrates potent inhibition of tumor cell growth, migration, and invasion in vitro with IC₅₀ values in the nanomolar range. Foretinib induces G2/M cell cycle arrest, suppresses HGF-induced motility, and reduces metastatic tumor nodules in xenograft models (Schwartz 2022, DOI). It is recommended for research use only, with specific solubility and storage requirements, and not intended for diagnostic use. Foretinib's multikinase profile enables advanced pathway analysis and translational research in oncology.

Biological Rationale

Receptor tyrosine kinases (RTKs) such as VEGFR, HGFR/Met, and PDGFR play central roles in cancer cell proliferation, survival, angiogenesis, and metastasis. Dysregulation of these kinases is frequently observed in solid and hematological malignancies. Inhibition of multiple RTKs can overcome redundancy and compensatory mechanisms that limit the efficacy of single-target agents (Schwartz 2022). Multikinase inhibitors like Foretinib have thus emerged as essential tools for elucidating oncogenic signaling and for preclinical evaluation of anti-cancer strategies.

Mechanism of Action of Foretinib (GSK1363089)

Foretinib (GSK1363089) is a small-molecule ATP-competitive inhibitor that targets a spectrum of receptor tyrosine kinases:

• Primary targets: c-Met (HGFR), VEGFR2 (KDR), VEGFR1 (Flt-1), VEGFR3 (Flt-4)
• Secondary targets: Ron, KIT, Flt-3, PDGFR-α, PDGFR-β, Tie-2

Foretinib binds competitively at the ATP-binding site of these kinases, resulting in potent inhibition of their phosphorylation and downstream signaling cascades. The reported biochemical IC₅₀ values for these targets range from 0.4 to 9.6 nmol/L under standard in vitro assay conditions (APExBIO). In cellular assays (e.g., B16F10, PC-3, A549, HT29), Foretinib inhibits MET signaling with IC₅₀ values between 21–23 nmol/L. This leads to disruption of cell cycle progression at G2/M, decreased proliferation, and impaired cell motility, particularly in the presence of hepatocyte growth factor (HGF).

Evidence & Benchmarks

• Foretinib demonstrates kinase inhibition with IC₅₀ values of 0.4–9.6 nmol/L for Met, VEGFR2, VEGFR1, VEGFR3, KIT, Flt-3, PDGFR-α/β, and Tie-2 in in vitro kinase assays (APExBIO).
• In cellular models, Foretinib inhibits MET phosphorylation in B16F10 and PC-3 cells at ~21–23 nmol/L, reducing proliferation and migration (Schwartz 2022, DOI).
• Foretinib suppresses HGF-induced cell motility and induces G2/M cell cycle arrest, as shown in HT29 and A549 cell lines under serum-stimulated conditions (Schwartz 2022, DOI).
• In vivo, oral dosing at 30 mg/kg in mouse ovarian cancer xenograft models reduces metastatic nodules and tumor weight versus vehicle controls (APExBIO).
• Foretinib achieves solubility ≥31.65 mg/mL in DMSO but is insoluble in water and ethanol at room temperature (product data sheet).

For a detailed comparison of Foretinib's efficacy with other kinase inhibitors and its unique multikinase profile, see this article, which our current article extends by providing updated in vivo and workflow parameters for translational research.

For optimization tips and comparative insights in assay workflows, refer to this workflow guide; the present article adds new quantitative benchmarks and addresses solubility/storage parameters.

Applications, Limits & Misconceptions

Foretinib is used extensively in:

• In vitro kinase inhibition and cell viability assays for mechanistic oncology research
• Migration and invasion assays, particularly in HGF-stimulated environments
• In vivo xenograft and metastasis models (especially ovarian, melanoma, prostate, lung, and colon cancers)
• Pathway dissection studies involving VEGF and HGF/Met signaling

For advanced quantification of cell motility and growth inhibition, see this recent article, which is clarified here by explicit solubility and handling instructions tailored for reproducible results.

Common Pitfalls or Misconceptions

• Diagnostic/therapeutic use: Foretinib (GSK1363089) is for research use only; it is not approved for clinical or diagnostic applications (APExBIO).
• Solubility limitations: Foretinib is insoluble in water and ethanol; DMSO is required for stock preparations (≥31.65 mg/mL at RT).
• Degradation risk: Extended storage above -20°C or repeated freeze-thaw cycles may degrade Foretinib and reduce activity.
• Cell line specificity: IC₅₀ values and efficacy vary by cell line, passage number, and assay conditions.
• Non-selectivity: Foretinib inhibits multiple kinases, which may confound pathway-specific studies without appropriate controls.

Workflow Integration & Parameters

For optimal use of Foretinib in cancer research workflows:

• Prepare stock solutions in DMSO at ≥31.65 mg/mL; store at -20°C in aliquots to avoid degradation.
• Use freshly diluted working solutions, and minimize freeze-thaw cycles.
• Typical in vitro assay concentrations: 1–100 nM, depending on cell type and endpoint.
• For in vivo studies, oral dosing at 30 mg/kg has demonstrated efficacy in reducing tumor nodules in mouse xenograft models (Schwartz 2022).

Foretinib is available from APExBIO as the A2974 kit for research applications. For further reading on translational workflows and troubleshooting, see this detailed guide, which this article updates with expanded evidence and critical handling notes.

Conclusion & Outlook

Foretinib (GSK1363089) is a validated, nanomolar-potency multikinase inhibitor that facilitates advanced cancer research by targeting VEGFR, HGFR/Met, and related pathways. Its robust in vitro and in vivo efficacy, well-characterized solubility, and defined storage parameters make it a reliable tool for pathway dissection and translational oncology studies. Strict adherence to preparation and storage guidelines is essential for reproducible results. As the landscape of kinase-targeted therapeutics evolves, Foretinib remains a benchmark compound for mechanistic and preclinical investigations in oncology (Schwartz 2022).